PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

Intellia Therapeutics, Inc. (NTLA)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINUS45826J1051
CUSIP45826J105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.65B
EPS-$5.34
Revenue (TTM)$51.77M
Gross Profit (TTM)-$367.86M
EBITDA (TTM)-$476.94M
Year Range$22.67 - $47.48
Target Price$76.00
Short %11.96%
Short Ratio5.74

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%80.00%100.00%120.00%JulyAugustSeptemberOctoberNovemberDecember
39.55%
123.35%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with NTLA

Intellia Therapeutics, Inc.

Popular comparisons: NTLA vs. CRSP, NTLA vs. SCHD, NTLA vs. AAPL, NTLA vs. GOOGL

Return

Intellia Therapeutics, Inc. had a return of -11.61% year-to-date (YTD) and -32.66% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-11.61%19.67%
1 month20.94%8.42%
6 months-24.71%7.29%
1 year-32.66%12.71%
5 years (annualized)11.50%10.75%
10 years (annualized)N/A9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-1.30%9.45%3.80%-11.46%-15.64%-20.78%18.28%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
NTLA
Intellia Therapeutics, Inc.
-0.66
^GSPC
S&P 500
0.91

Sharpe Ratio

The current Intellia Therapeutics, Inc. Sharpe ratio is -0.66. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.66
0.91
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Dividend History


Intellia Therapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-82.55%
-4.21%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Intellia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intellia Therapeutics, Inc. was 86.90%, occurring on Oct 27, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-86.9%Sep 7, 2021540Oct 27, 2023
-72.99%Mar 12, 2018507Mar 16, 2020178Nov 25, 2020685
-61.52%Jun 1, 2016251May 30, 201788Oct 3, 2017339
-44.32%Jan 20, 202133Mar 8, 202134Apr 26, 202167
-44.12%Nov 1, 201731Dec 14, 201756Mar 8, 201887

Volatility Chart

The current Intellia Therapeutics, Inc. volatility is 27.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
27.00%
2.79%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)